Free Trial

Belite Bio (BLTE) 10K Form and Latest SEC Filings 2026

Belite Bio logo
$154.38 -0.13 (-0.08%)
Closing price 04:00 PM Eastern
Extended Trading
$154.75 +0.37 (+0.24%)
As of 06:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Belite Bio SEC Filings & Recent Activity

Belite Bio (NASDAQ:BLTE) has submitted 134+ documents to the U.S. Securities and Exchange Commission (SEC) since 2022. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Belite Bio's financial statements. The most recent filing was a Form 4 submitted on May 4, 2026.

Form 4
BELITE BIO, INC Reports Ownership Change on May. 4, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

20-F
Belite Bio Files Annual Report on Mar. 31, 2026

The 20-F contains Belite Bio's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Belite Bio SEC Filing History

Browse Belite Bio's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/04/2026 3:15 PM
Belite Bio (1889109) Issuer
MATA NATHAN L. (2013987) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/29/2026 3:32 PM
Belite Bio (1889109) Issuer
MATA NATHAN L. (2013987) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/27/2026 3:52 PM
Belite Bio (1889109) Issuer
MATA NATHAN L. (2013987) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/24/2026 3:15 PM
Belite Bio (1889109) Issuer
MATA NATHAN L. (2013987) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/23/2026 3:23 PM
Belite Bio (1889109) Issuer
Lin Yu-Hsin (1965964) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/23/2026 3:17 PM
Belite Bio (1889109) Issuer
Chuang Hao-Yuan (1992008) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/23/2026 3:19 PM
Belite Bio (1889109) Issuer
MATA NATHAN L. (2013987) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/23/2026 3:20 PM
Belite Bio (1889109) Issuer
Scholl Hendrik Peter (2113223) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/22/2026 3:15 PM
Belite Bio (1889109) Issuer
MATA NATHAN L. (2013987) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/21/2026 4:28 PM
Belite Bio (1889109) Issuer
MATA NATHAN L. (2013987) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/21/2026 3:00 PM
Belite Bio (1889109) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/20/2026 3:15 PM
Belite Bio (1889109) Issuer
MATA NATHAN L. (2013987) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 3:15 PM
Belite Bio (1889109) Issuer
MATA NATHAN L. (2013987) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/16/2026 3:15 PM
Belite Bio (1889109) Issuer
MATA NATHAN L. (2013987) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 4:23 PM
Belite Bio (1889109) Subject
MATA NATHAN L. (2013987) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/13/2026 3:15 PM
Belite Bio (1889109) Issuer
Chuang Hao-Yuan (1992008) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/13/2026 3:15 PM
Belite Bio (1889109) Issuer
Chen Wan-Shan (2001438) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/13/2026 3:15 PM
Belite Bio (1889109) Issuer
Lin Yu-Hsin (1965964) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/09/2026 3:52 PM
Belite Bio (1889109) Subject
Lin Yu-Hsin (1965964) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/09/2026 3:43 PM
Belite Bio (1889109) Subject
Chuang Hao-Yuan (1992008) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/09/2026 11:17 AM
Belite Bio (1889109) Subject
Chen Wan-Shan (2001438) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/31/2026 7:00 AM
Belite Bio (1889109) Filer
Form 20-F
Registration statement / Annual report / Transition report  
03/31/2026 7:01 AM
Belite Bio (1889109) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/18/2026 2:32 PM
Belite Bio (1889109) Issuer
Scholl Hendrik Peter (2113223) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 1:38 PM
Belite Bio (1889109) Issuer
Chuang Hao-Yuan (1992008) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 1:45 PM
Belite Bio (1889109) Issuer
MATA NATHAN L. (2013987) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 1:28 PM
Belite Bio (1889109) Issuer
Biddle Gary Clark (2107993) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 1:29 PM
Belite Bio (1889109) Issuer
Lu Ita (2107173) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 1:33 PM
Belite Bio (1889109) Issuer
Longo John Michael (2106601) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 1:36 PM
Belite Bio (1889109) Issuer
Chen Xiao-Hui (2106182) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 1:12 PM
Belite Bio (1889109) Issuer
Chen Wan-Shan (2001438) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 1:24 PM
Belite Bio (1889109) Issuer
Lin Yu-Hsin (1965964) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/02/2026 5:01 AM
Belite Bio (1889109) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/30/2026 7:00 AM
Belite Bio (1889109) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
01/27/2026 7:00 AM
Belite Bio (1889109) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/10/2025 3:30 PM
Belite Bio (1889109) Subject
Darwin Global Management, Ltd. (1839209) Filed by
Form SCHEDULE 13G
12/01/2025 4:12 PM
Belite Bio (1889109) Filer
Form 424B5
12/01/2025 5:01 AM
Belite Bio (1889109) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/10/2025 7:00 AM
Belite Bio (1889109) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/22/2025 7:00 AM
Belite Bio (1889109) Filer
Form F-3ASR
10/17/2025 8:29 AM
Belite Bio (1889109) Subject
Chen Wan-Shan (2001438) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/16/2025 11:26 AM
Belite Bio (1889109) Subject
Chen Wan-Shan (2001438) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/14/2025 2:05 PM
Belite Bio (1889109) Subject
Chuang Hao-Yuan (1992008) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/14/2025 11:44 AM
Belite Bio (1889109) Subject
Chen Wan-Shan (2001438) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/18/2025 3:38 PM
Belite Bio (1889109) Subject
Lin Yu-Hsin (1965964) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/08/2025 7:00 AM
Belite Bio (1889109) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/21/2025 4:17 PM
Belite Bio (1889109) Subject
MATA NATHAN L. (2013987) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/11/2025 5:02 AM
Belite Bio (1889109) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/08/2025 8:01 AM
Belite Bio (1889109) Filer
Form 424B5
08/07/2025 7:21 AM
Belite Bio (1889109) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/02/2025 5:02 AM
Belite Bio (1889109) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/21/2025 3:30 PM
Belite Bio (1889109) Subject
Lin Yu-Hsin (1965964) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/21/2025 5:01 AM
Belite Bio (1889109) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/13/2025 8:23 PM
Belite Bio (1889109) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)

Belite Bio SEC Filings - Frequently Asked Questions

Belite Bio (BLTE) has submitted 134+ filings to the SEC since 2022. You can browse the complete history or filter by form type using the tools above.

Belite Bio's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Belite Bio's financial statements page.

The most recent filing was a Form 4 submitted on May 4, 2026. This was an insider ownership change filed by 4 - BELITE BIO, INC (0001889109) (Issuer).

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:BLTE) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners